A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

About the study

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²)
Have either

no T2D with an HbA1c < 6.5% or
have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening.
Have been diagnosed with chronic kidney disease (CKD).

EXCLUSION CRITERIA

Exclusion Criteria:

Have a self-reported change in body weight >5 kilogram (kg) (11 pounds) within 90 days before screening.
Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin
Have a prior or planned surgical treatment for obesity
Have Type 1 Diabetes (T1D)
Have acute or chronic hepatitis
Have a history of malignant disease within 5 years before screening.